MedPath

Evaluation of the anti-inflammatory effect of bromfenac eye drops after cataractsurgery in patients with pseudoexfoliatio of the lens

Conditions
Postoperative inflammation in patients with pseudoexfoliatio lentis undergoing cataractsurgery
Therapeutic area: Diseases [C] - Eye Diseases [C11]
Registration Number
EUCTR2013-002066-39-IT
Lead Sponsor
Azienda Ospedaliera di Reggio Emilia Arcispedale S.Maria Nuova/IRCCS
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Patients with cataract:
- with nuclear sclerosis of the crystalline lens graded 1 or more according to the LOCS
II classification (Lens opacities classification system II; Chylack LT et al. 1989);
- with classics sign of pseudoesfoliatio lentis (PEX).
The diagnosis of PEX will be made by demonstrating the pathognomonic white deposits
in the lens, cornea, iris and anterior hyaloid face by slit lamp examination.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 10
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 52

Exclusion Criteria

Patients with history of ocular inflammation or trauma, previous intraocular surgery,
corneal haze, retinal vascular disease, diabetic retinopathy, variation of the foveal
profile at OCT (including macular edema and epiretinal membrane), moderate to
severe age related macular degeneration or age < 60 year will be excluded. Only one
eye per patient will be included in our study.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath